IMMUNE THERAPEUTICS WELCOMES AMB JACK BREWER TO THE BOARD OF
DIRECTORS
Orlando, FL -- September 06, 2018 -- InvestorsHub NewsWire
-- Immune
Therapeutics, Inc. (OTC:IMUN) (IMUN) ("Immune" "IMUN" or the
"Company"), a clinical late-stage T-Cell Activation
biopharmaceutical company focused on the development
immunotherapies for the treatment of autoimmune and inflammatory
conditions, cancer, HIV/AIDS and animal diseases on a global basis,
announced today that Mr. Jack Brewer, MBA, has joined the Company
as a member of the Board of Directors.
Mr.
Brewer, founder and CEO of
The Brewer Group Companies (TBG) and a former wealth
manager with Merrill Lynch, currently manages The Brewer
Group's private
portfolio,
which focuses on impact investing. Mr. Brewer also
serves as a frequent business contributor on Fox Business and
appears on national and international media outlets
such as
CNN, CNN
International, CNBC, MSNBC, CNBC, CCTV and Sky News. Mr. Brewer is
a former football safety who played professionally in the National
Football League, where he was a captain on the Minnesota
Vikings, New York Giants and the Philadelphia Eagles.
Mr. Brewer
currently mentors
and helps several professional athletes as they
transition from sports to business. Brewer earned his Bachelor of
Science (2001) and his Masters in Sport Management (2002) from the
University of Minnesota, all while playing Division I football.
Additionally, he has completed Executive Business Programs at
Harvard School of Business (2005) and the Wharton School of
Business (2006), and is currently pursuing his Masters in
International Affairs from Colombia University. Brewer is currently
completing the Executive MBA program at the University of Miami
where he is spearheading Brewer Sports International's education
program to be the largest post-secondary degree program in
professional sports, having graduated over 40 current and former
professional athletes with EMBA degrees in its first graduating
class.
"I'm very excited
about the
opportunity to add my experience in
entrepreneurial
ventures to Immune Therapeutics during
this period of assigning new leadership
talent,"
stated Mr. Brewer. Mr. Brewer
further
stated that, "Through its recent
pivot, Immune Therapeutics
exhibits
the business and
social impact
that I respect, and I believe I can further assist in
unlocking their potential."
As Founder and
Executive Director of the Jack Brewer Foundation, Mr. Brewer
has worked for more than a
decade to
empower women and children living in impoverished and
underdeveloped communities by enabling food security; promoting
access to education and cultural exchanges; assisting in medical
aid and disaster relief; and building peace.
Over the past
five years, Mr. Brewer has helped Immune
Therapeutics with their expansion plans into international
markets, such as Malawi and
Haiti, and has recently began work
to help Immune Therapeutics expand registration into
India.
"Mr. Brewer
brings a wealth of experience in finance and capital investment to
Immune Therapeutics and has been instrumental in guiding us
in
our
efforts to expand to overseas markets. I'm extremely
pleased to welcome him as the newest member of the Immune
Therapeutics Board of Directors," stated Roscoe
Moore Jr.,
DVM, MPH, Ph.D., DSc, Immune Therapeutics Chairmen of the Board and
Scientific Advisory Board Member.
Dr. Gary Blick, a
member of the Company's Scientific Advisory Board stated,
"I am extremely excited about
the addition of
Jack
Brewer, to the Immune Board of Directors. Jack's
passionate work with his nonprofit foundation, his work with
JBF
Worldwide (and all its global
initiatives), along with
his
helping the
underserved and disenfranchised with unique educational and
economic opportunities, as well as his extensive business career
leading to becoming the
CEO and Executive
Producer of The Brewer Group, Inc. make Jack an invaluable asset to
Immune. I look forward to working
with him to help further Immune Therapeutics mission
and vision."
"Jack Brewer is a
strong addition to our team," said Noreen Griffin, CEO and Director
of Immune Therapeutics. Ms. Griffin continued, "His influence and
background, both in finance and emerging
markets, offers a tremendous resource
to our organization as we focus on various products in development.
The timing is perfect as we are establishing a team of well-respected
authorities in the industry."
ABOUT IMMUNE THERAPEUTICS, INC.
Immune
Therapeutics, Inc. is a late-stage biopharmaceutical company
focused on the development and commercialization of highly
innovative immunotherapies. Immune Therapeutics is actively
developing T-Activation immunotherapies to achieve immunomodulation
in patients both human and pets with autoimmune and inflammatory
disease, cancer and infectious diseases.
FORWARD LOOKING STATEMENTS
This release may
contain forward-looking statements. Actual results may differ from
those projected due to a number of risks and uncertainties,
including, but not limited to, the possibility that some or all the
matters and transactions considered by the Company may not proceed
as contemplated, and by all other matters specified in the
Company's filings with the Securities and Exchange Commission.
These statements are made based upon current expectations that are
subject to risk and uncertainty. The Company does not undertake to
update forward-looking statements in this news release to reflect
actual results, changes in assumptions or changes in other factors
affecting such forward-looking information. Assumptions and other
information that could cause results to differ from those set forth
in the forward-looking information can be found in the Company's
filings with the Securities and Exchange Commission (www.sec.gov),
including its recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/
IR contact
David Donlin
Cervelle Group
407-490-6635
info@thecervelle.com